Clinical trials: Contrast Enhancement in Magnetic Resonance Imaging
Rotator Cuff Tear, Labral Tear
Phase 3 Study of the Efficacy and Safety of MR Arthrography Using the NEMO-103 Injection in Patients With Known or Suspected Shoulder Joint Diseases
The goal of this Phase 3 clinical trial is to evaluate whether MR arthrography enhanced with NEMO-103 injection (NEMO-103 Inj.) provides superior diagnostic imaging quality compared to unenhanced MRI in patients with known or…
- Conditions
- Rotator Cuff Tear, Labral Tear, Rotator Cuff Tendinosis, Rotator Cuff Tendonitis
- Trial name
- NCT07057037
- Testing
- NEMO-103 Injection
- Where
- 8 sites in South Korea
- Volunteers
- 85 people
- Sponsor
- Inventera Inc.
Transplantation, Kidney, Graft Occlusion, Vascular
GFR Measurement With Contrast-enhanced Dynamic MRI
The aim of the study is to optimize and validate this MR-based GFR measurement in patients with a renal transplant, compared with the reference method, the Cr51- EDTA method: to select the most accurate combination of…
- Trial name
- IREN (NCT00614081)
- Testing
- Contrast-enhanced dynamic MRI
- Where
- France
- Volunteers
- 71 people
- Sponsor
- University Hospital, Bordeaux
Carotid Stenosis
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days.
- Trial name
- GEMSAV (NCT01344447)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 56 sites in United States, Argentina and 12 more
- Volunteers
- 479 people
- Sponsor
- Bayer
Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion
A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients
This is an operationally combined Phase 2/3 study, which will be conducted and evaluated in 2 distinct parts: Phase 2: Prospective, adaptive, multicenter, non-randomized, single-blind, dose-finding, including participants with…
- Trial name
- LUMINA (NCT07472491)
- Testing
- Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL, MRI Scan, Gadobutrol
- Where
- 7 sites in United States, Georgia and 2 more
- Volunteers
- 640 people
- Sponsor
- GE Healthcare
Contrast-Enhanced Magnetic Resonance Imaging Detection
Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function
This is an open-label, non-randomized, parallel cohorts design, multicenter, single dose phase I study. The primary objectives are: To evaluate the pharmacokinetics (plasma and urine) profile of HRS-9231 following single…
- Trial name
- NCT06657560
- Testing
- HRS-9231
- Where
- China
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd
Bladder Cancer, Staging
Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale
Bladder cancer is the most common malignant tumor of the urinary system. The presence or absence of muscle invasion in early bladder cancer is an independent prognostic factor.
- Conditions
- Bladder Cancer, Staging, Deep Learning, Neoadjuvant Chemotherapy
- Trial name
- MICS-BC (NCT07051083)
- Testing
- Risk Stratification
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Vascular Diseases
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients
The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of vascular diseases in patients of Chinese origin.
- Trial name
- NCT00395733
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875), Gadopentate dimeglumine (Magnevist, BAY86-4882)
- Where
- 3 sites in China
- Volunteers
- 83 people
- Sponsor
- Bayer
Pulmonary Congestion
Thoracic Fluid Assessment by Contrast-enhanced Magnetic Resonance Imaging and Bioimpedance
Heart failure (HF) is a major health problem, which is characterized by reduced cardiac function leading to pulmonary congestion. Most episodes of acute HF requiring unplanned hospitalization are due to pulmonary congestion.
- Trial name
- NCT02364193
- Testing
- MRI, Gd-CA, BIS ImpediMed™ SFB7
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Catharina Ziekenhuis Eindhoven
Renal Artery Stenosis
Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal Arteries
The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Magnevist (the study drug) used for MRI of the renal arteries.
- Trial name
- NCT00310557
- Testing
- Gadopentetate dimeglumine (Magnevist)
- Volunteers
- 116 people
- Sponsor
- Bayer
Fibrosis and Cirrhosis of Liver
Quantitative MRI Imaging in Diffuse Liver Diseases
As we all know, the early diagnosis and accurate staging of liver fibrosis are very important to reduce the incidence of liver cirrhosis and liver cancer.
- Trial name
- QMIDLD (NCT04626492)
- Testing
- Quantitative MRI imaging
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Diabetes Mellitus, Heart Failure
Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction
The purpose of this study is to evaluate the results of 99mTc maraciclatide scintigraphy in diabetic subjects with HFPEF. A maximum of 20 subjects with Diabetes Mellitus (DM) and Heart Failure With Preserved Left Ventricular…
- Trial name
- NCT01440517
- Testing
- Tc99m-Maraciclatide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- GE Healthcare
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
The purpose of this study is to find out what effects pazopanib (pazopanib hydrochloride) (also called Votrient®) may have on MRI (magnetic resonance imaging) scans, blood pressure, and various proteins in the blood.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01599832
- Testing
- pazopanib hydrochloride, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Contrast Enhancement in Magnetic Resonance Imaging, Healthy Volunteers
A Study to Learn More About the Safety and the Level of BAY 1747846 in Body Given as Injection Into the Vein at Increasing Single Doses in Japanese Healthy Male Participants
The goal of this clinical study was to learn more about BAY1747846 compared to placebo when given as an injection into the vein in Japanese healthy male participants: the safety of BAY1747846 when given at increasing single doses…
- Trial name
- NCT06125366
- Testing
- BAY1747846
- Where
- Japan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bayer
Crohn's Disease
CE-U and MRE to Predict the Efficacy of Anti-TNF Therapy in Crohn's Disease
The value of anti-TNF therapy in intestinal strictures related to Crohn's disease (CD) has not been clearly demonstrated. The results reported by some teams suggest no beneficial effect or even an increased risk of bowel…
- Trial name
- CREOLE (NCT01183403)
- Where
- 18 sites in Belgium, France
- Volunteers
- 80 people
- Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Magnetic Resonance Imaging Contrast Agents
Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography
Rationale: Dotarem provides superior enhancement characteristics compared to other GBCA in fMRU Specific Aims: Compare enhancement characteristics of Dotarem to other GBCAs in the kidneys used in fMRU Primary Objectives: Review…
- Trial name
- NCT03910114
- Testing
- Magnevist, Dotarem, Gadovist
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- Vanderbilt University Medical Center